-
公开(公告)号:US12076366B2
公开(公告)日:2024-09-03
申请号:US16920652
申请日:2020-07-03
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Christopher So , Howard P. Sard , Vishnumurthy Hegde
CPC classification number: A61K38/10 , A61K9/0019 , A61K38/22 , A61K47/551 , A61K47/60
Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
-
公开(公告)号:US09616109B2
公开(公告)日:2017-04-11
申请号:US14919572
申请日:2015-10-21
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Howard Sard , Vishnumurthy Hegde
CPC classification number: A61K38/28 , A61K9/0019 , A61K47/551 , A61K47/60 , A61K47/64 , C07K14/62
Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
-
公开(公告)号:US20150065420A1
公开(公告)日:2015-03-05
申请号:US14542581
申请日:2014-11-15
Applicant: EXTEND BIOSCIENCES, INC.
Inventor: Tarik Soliman , Laura M. Hales , Howard P. Sard , Mukkanti Amere
CPC classification number: A61K47/60 , A61K38/22 , A61K47/551
Abstract: The invention provides carriers that enhance the absorption, half-life or bioavailability of Ghrelin peptides. The carriers comprise targeting groups that bind the Vitamin D Binding protein (DBP), conjugation groups for coupling the targeting groups to the therapeutic compounds, and optionally scaffolding moieties.
Abstract translation: 本发明提供增强Ghrelin肽的吸收,半衰期或生物利用度的载体。 载体包含结合维生素D结合蛋白(DBP)的靶向基团,用于将靶向基团偶联到治疗化合物的缀合基团,以及任选的支架部分。
-
公开(公告)号:US12233115B2
公开(公告)日:2025-02-25
申请号:US18368347
申请日:2023-09-14
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Daniel B. Hall , Rachel Covitz , Garry Musso , Caroline Hill , Ahmet Vakkasoglu , Poul Strange , Tilmann M. Brotz
Abstract: The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position of a non-hormonal vitamin D via a scaffold of discreet length that facilitates its purification, detection, solubility, and efficacy at the PTH receptor (PTHR). The PTH may be conjugated to the non-hormonal vitamin D via a 36 mer poly(ethylene glycol) moiety (PTH-PEG36-VitD). The invention also provides optimized manufacturing methods and formulations. The PTH-PEG36-VitD has a vastly-improved serum half-life and bioavailability when compared to a non-conjugated PTH peptide. PTH-PEG36-VitD also significantly increases serum calcium, reduces urinary calcium, and reduces serum phosphate.
-
公开(公告)号:US10702574B2
公开(公告)日:2020-07-07
申请号:US15430449
申请日:2017-02-11
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Christopher So , Howard P. Sard , Vishnumurthy Hegde
Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
-
公开(公告)号:US20190183966A1
公开(公告)日:2019-06-20
申请号:US16261507
申请日:2019-01-29
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Christopher So , Howard P. Sard , Vishnumurthy Hegde
CPC classification number: A61K38/10 , A61K9/0019 , A61K38/22 , A61K47/551 , A61K47/60
Abstract: The invention provides a parathyroid hormone (PTH) compound comprising a PTH peptide. The PTH compound has a significantly increased bioavailability or circulating half-life when compared to a bioavailability or a circulating half-life of a native form of the PTH peptide. The PTH compound has a significantly greater serum concentration at multiple timepoints post-administration to a rat when compared to that of a native PTH peptide.
-
公开(公告)号:US20170252410A1
公开(公告)日:2017-09-07
申请号:US15468083
申请日:2017-03-23
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Howard Sard , Vishnumurthy Hegde
Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
-
公开(公告)号:US20160114049A1
公开(公告)日:2016-04-28
申请号:US14919671
申请日:2015-10-21
Applicant: EXTEND BIOSCIENCES, INC.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Howard P. Sard , Vishnumurthy Hegde
IPC: A61K47/48 , A61K31/713
CPC classification number: A61K47/551 , A61K31/00 , A61K31/713 , A61K47/60
Abstract: The invention provides non-hormonal vitamin D conjugated to therapeutic RNA compounds that result in the compounds having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the therapeutic RNA compounds via the third carbon on the vitamin D backbone.
Abstract translation: 本发明提供与治疗性RNA化合物缀合的非激素维生素D,当与非共轭形式相比时,其导致具有增加的吸收,生物利用度或循环半衰期的化合物。 维生素D靶向组通过维生素D主链上的第三个碳原子与治疗性RNA化合物偶联。
-
公开(公告)号:US20160114001A1
公开(公告)日:2016-04-28
申请号:US14919572
申请日:2015-10-21
Applicant: EXTEND BIOSCIENCES, INC.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Howard Sard , Vishnumurthy Hegde
CPC classification number: A61K38/28 , A61K9/0019 , A61K47/551 , A61K47/60 , A61K47/64 , C07K14/62
Abstract: The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
Abstract translation: 本发明提供与胰岛素肽缀合的非激素维生素D,当与非共轭形式相比时,导致肽具有增加的吸收,生物利用度或循环半衰期。 维生素D靶向组通过维生素D骨架上的第三个碳原子连接到胰岛素肽上。
-
公开(公告)号:US20180311307A1
公开(公告)日:2018-11-01
申请号:US16034046
申请日:2018-07-12
Applicant: Extend Biosciences, Inc.
Inventor: Tarik Soliman , Laura M. Hales , Daniel B. Hall , Christopher So , Howard P. Sard , Vishnumurthy Hegde
CPC classification number: A61K38/10 , A61K9/0019 , A61K38/22 , A61K47/551 , A61K47/60
Abstract: The invention provides non-hormonal vitamin D conjugated via the third carbon on the vitamin D backbone to parathyroid hormone (PTH) proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms.
-
-
-
-
-
-
-
-
-